Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PRHSX vs. RYHIX: which is better?

Bottom line

PRHSX vs RYHIX: the short answer

PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 70% by weight.

But PRHSX is far broader, holding 279 positions to 135 for RYHIX, so beyond the top names it adds exposure RYHIX doesn't have.

PRHSX is cheaper at 0.83% vs 1.38% — a difference of $55 a year per $10,000 invested.

Over five years, RYHIX returned +5.1% a year vs +4.2% for PRHSX.

Updated Nov 19, 2026

PRHSX vs RYHIX side by side

PRHSXRYHIX
TypeMutual fundMutual fund
Fund familyT. Rowe PriceGuggenheim
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.83%1.38%
Annual cost per $10k$83$138
10-yr cost on $10k (prospectus)$1,025$1,709
Max front load——
12b-1 fee—0%
1-yr return+17.7%+14.4%
5-yr return (annualized)+4.2%+5.1%
10-yr return (annualized)+9.1%+7.9%
Best quarter+23.5%+18.7%
Worst quarter−15.8%−14.4%
Net assets (fund)$11.9B$19.4M
Number of holdings279135
Portfolio turnover62%244%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPRHSXRYHIXDifference
2025+17.7%+14.4%+3.3%
2024+1.8%+0.6%+1.2%
2023+3.1%+5.8%−2.8%
2022−12.2%−11.6%−0.6%
2021+13.3%+19.2%−6.0%
2020+30.1%+18.9%+11.2%
2019+29.1%+22.8%+6.3%
2018+1.2%+1.6%−0.3%
2017+28.0%+23.5%+4.5%
2016−10.4%−9.4%−1.0%

Source: Fund prospectus bar charts

Holdings overlap

17 of PRHSX's top 25 holdings also appear in RYHIX's top 25.

Shared top holdings
HoldingPRHSXRYHIX
Eli Lilly & Co14.28%3.63%
Johnson & Johnson6.63%2.88%
Unitedhealth Group Inc5.99%2.22%
Abbvie Inc5.10%2.52%
Merck & Co. Inc.4.01%2.04%
Gilead Sciences Inc2.82%1.39%
Thermo Fisher Scientific Inc2.52%1.61%
Vertex Pharmaceuticals Inc2.28%1.34%
Bristol-myers Squibb Co2.11%1.22%
Abbott Laboratories1.89%1.42%
Intuitive Surgical Inc1.87%1.31%
Amgen Inc1.82%1.56%
Stryker Corp1.78%1.21%
Elevance Health Inc1.53%1.02%
Danaher Corp1.43%1.30%

Source: SEC Form N-PORT

PRHSX top 10

  1. Eli Lilly & Co — 14.28%
  2. Johnson & Johnson — 6.63%
  3. Unitedhealth Group Inc — 5.99%
  4. Abbvie Inc — 5.10%
  5. Merck & Co. Inc. — 4.01%
  6. Gilead Sciences Inc — 2.82%
  7. Thermo Fisher Scientific Inc — 2.52%
  8. Vertex Pharmaceuticals Inc — 2.28%
  9. Bristol-myers Squibb Co — 2.11%
  10. Abbott Laboratories — 1.89%

RYHIX top 10

  1. Eli Lilly & Company — 3.63%
  2. Johnson & Johnson — 2.88%
  3. Abbvie Inc — 2.52%
  4. Unitedhealth Group Inc — 2.22%
  5. Merck & Company Inc — 2.04%
  6. Thermo Fisher Scientific Inc — 1.61%
  7. Amgen Inc — 1.56%
  8. Abbott Laboratories — 1.42%
  9. Gilead Sciences Inc — 1.39%
  10. Vertex Pharmaceuticals Inc — 1.34%

FAQ

What is the difference between PRHSX and RYHIX?
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 70% by weight. But PRHSX is far broader, holding 279 positions to 135 for RYHIX, so beyond the top names it adds exposure RYHIX doesn't have.
Which is cheaper, PRHSX or RYHIX?
PRHSX has the lower expense ratio (0.83%).
Should I own both PRHSX and RYHIX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.